Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 381

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 381
---
 a director due to her extensive medical experience.

<div align='center'>208</div>

TABLE OF CONTENTS

#### Nicholas Fernandez
Mr. Fernandez has almost 20 years of experience across operations, accounting and finance. Mr. Fernandez has been with Athanor Capital, a hedge fund, since December 2019, most recently serving as Chief Operating Officer and Chief Financial Officer. Mr. Fernandez has chaired the Valuation Committee in addition to sitting on the Management Committee. Previously, he was the Chief Financial Officer of the Asset Management and Alternative Investments Divisions of Jeffries LLC, a global bulge bracket investment bank, from February 2017 to April, 2019. Prior to that, Mr. Fernandez worked at a variety of alternative investment managers in several capacities, progressing from a Fund Accountant to a Controller/Director of Operations. He started his career in public accounting with Ernst & Young in their Financial Services Office in New York, in their asset management practice with a concentration/serving Hedge, Private Equity and Venture Funds, as well as consulting. Mr. Fernandez earned a BS in Accounting and Finance with a minor in Business Administration from the University at Albany, SUNY. Mr. Fernandez holds an active Certified Public Accountant License in the state of New York. Mr. Fernandez serves on the Board of Iris Acquisition Corp. Mr. Fernandez was selected to serve as a director because of his experience in investment management, accounting and finance.

#### Ji Yeon Baek, MD, PhD
Dr. Baek has extensive clinical experience, combined with a track record of successfully leading impactful studies in colorectal and rectal cancer. Since March 2024, Dr. Baek has been a clinical professor at Korea University Guro Hospital. From 2009 to 2024, Dr. Baek was a research medical oncologist at National Cancer Center, Republic of Korea. From 2018 to 2019, she was a visiting investigator at Dana-Farber Cancer Center. Dr. Baek received her MD, MS and PhD at The Catholic University of Korea. Dr. Baek was selected to serve as a director due to her extensive medical experience.

#### Family Relationships
There are no family relationships among any of ParentCo’s directors or executive officers.

#### Corporate Governance

#### Composition of the ParentCo Board
ParentCo’s business and affairs will be organized under the direction of its board of directors. Chris Kim will serve as Chair of the Board. The primary responsibilities of the ParentCo Board will be to provide oversight, strategic guidance